slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 25,591-25,620
Pages 1,437
Rows per page 30
Arc
25,591-25,620 of 43,093
14
The chart uses a standard waterfall bridge format to reconcile cash balances.ModivCare | Investor Presentation Deck | 36 slides · ModivCare
Pitch deck Investor relations Beat · Financials1 hit
15
Includes footnotes explaining EBITDA adjustments and free cash flow calculation.ModivCare | Investor Presentation Deck | 36 slides · ModivCare
Pitch deck Investor relations Beat · Financials1 hit
16
2023 outlook excludes impact of M&A.ModivCare | Investor Presentation Deck | 36 slides · ModivCare
Pitch deck Investor relations Beat · Financials1 hit
03
Moelis & Company | Investor Presentation Deck | 24 slidesMoelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
04
The slide uses a three-column layout to categorize key performance indicators.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
17
The slide highlights organizational growth through a mix of internal talent development and external recruitment.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · TeamLoop · Why Now1 hit
18
The slide uses a combination of a horizontal bar chart and tabular data represented by circles to show market penetration and investment.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · Market SizeLoop · Why Now1 hit
04
Momentus | Results Presentation Deck | 17 slidesMomentus | Results Presentation Deck | 17 slides · Momentus
Conference presentation Investor relations Beat · Problem1 hit
05
Momentus | Results Presentation Deck | 17 slidesMomentus | Results Presentation Deck | 17 slides · Momentus
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses an orbital path visual to represent a chronological sequence of space missions.Momentus | Results Presentation Deck | 17 slides · Momentus
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
Momentus | Results Presentation Deck | 17 slidesMomentus | Results Presentation Deck | 17 slides · Momentus
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Includes a photo of customers integrating a payload at Momentus HQ.Momentus | Results Presentation Deck | 17 slides · Momentus
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Momentus | Results Presentation Deck | 17 slidesMomentus | Results Presentation Deck | 17 slides · Momentus
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
14
Includes a disclaimer/note about backlog at the bottom.Momentus | Results Presentation Deck | 17 slides · Momentus
Conference presentation Investor relations Beat · Financials1 hit
04
Includes product milestones for Hero Wars, Pixel Gun 3D, and Island Hoppers, alongside comparative financial charts (Q3'22 vs Q3'23).Nexters | Results Presentation Deck | 11 slides · GDEV Inc.
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a series of bar charts to show year-over-year performance, with percentage change annotations.Nexters | Results Presentation Deck | 11 slides · GDEV Inc.
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
06
Includes percentage growth/decline annotations for each pair of bars.Nexters | Results Presentation Deck | 11 slides · GDEV Inc.
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
06
Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
07
Uses a visual process flow to contrast standard therapy failure with Nuvalent's mechanism.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The table highlights the clinical gap in patients with prior kinase inhibitor treatment, specifically those with G2032R mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
13
The slide uses dot plots for IC50 values and a bar chart for tumor regression, highlighting NVL-520's performance.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
14
The slide uses a bar chart to show brain penetrance and a grouped bar chart to show selectivity index, highlighting the drug's potential to avoid off-target CNS effects.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a side-by-side comparison layout to distinguish between the dose escalation (Phase 1) and the registrational intent (Phase 2) study designs.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
16
The slide details the transition from the all-treated population to the NSCLC response-evaluable population.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
17
The table highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy and 71% having received 2 or more prior ROS1 TKIs.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
18
Data as of 13 Sep 22. N=35 patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
19
The chart displays dose-dependent exposure levels exceeding multiple efficacy thresholds for ROS1 variants in CNS and peripheral tissues.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
20
Clinical trial data table showing efficacy metrics for NVL-520 in NSCLC patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
The chart is a swimmer plot, commonly used in oncology to visualize time-to-event data for individual patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit